AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 282 min read$LLY

Lilly’s retatrutide beats Ozempic in head-to-head trial

Eli Lilly's retatrutide outperformed Novo Nordisk's Ozempic in a Phase III trial, achieving 19.5-20.9% weight loss vs. Ozempic's 9.4%, and greater A1C reduction. Retatrutide also improved cardiovascular risk factors. Lilly and Novo are competitors in the obesity and type 2 diabetes market, with ongoing legal and market disputes.

Original reporting
finance.yahoo.com
Published Oct 28, 2026, 6:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 6:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Lilly’s retatrutide beats Ozempic in head-to-head trial — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$LLYBullishMed
01

Why it matters

The trial data give Lilly a clear efficacy edge, which could translate into higher market share and revenue growth if approved.

02

Market read

First‑time disclosure of comparative Phase III results that favor Lilly, likely influencing investor sentiment and stock price.

03

What to watch

Regulatory approval timeline and manufacturing scale could temper near‑term impact.

Relevance 8/10Novelty 8/10Timing: same‑day release

Background

Eli Lilly and Novo Nordisk are the two dominant players in GLP‑1 obesity/diabetes therapies.

Company-level read

Ticker impact

$LLYBullishHigh confidence
Context

Phase III TRANSCEND-T2D-2 trial shows Lilly's retatrutide delivers double the weight loss and greater A1C reduction versus Novo's Ozempic.

Expected impact

likely upward pressure as investors price in a competitive advantage for retatrutide.

Evidence & confidence

First disclosure of head‑to‑head Phase III results; data are materially better than competitor, creating upside potential.

Market effects

Sector

Weight‑loss/diabetes sector may see re‑rating of GLP‑1 competitors.

Regional

U.S. biotech and pharma markets could see modest gains.

Global

Potential shift in global obesity‑treatment landscape.

Counterpoint

What could challenge this read

If the market has already priced in the data, the upside may be limited.

Key entities

  • company
    Eli Lilly

    Developer of retatrutide, a triple‑agonist obesity/diabetes drug.

  • company
    Novo Nordisk

    Maker of Ozempic, the current market leader in GLP‑1 therapy.

Read at source← All news

StoryEli Lilly’s retatrutide cuts A1C and weight far more than Ozempic in Phase 3 head‑to‑head trial

Also covered by

6 outlets

Related articles

OCT 28
$LLYMedAI 8/10

Eli Lilly’s ‘Triple-G’ Drug Tops Ozempic in Head-to-Head Type 2 Diabetes Trial

Eli Lilly's experimental drug retatrutide showed greater improvement in type 2 diabetes measures than Novo's Ozempic in a Phase 3 trial, reducing A1C levels by 2.2 points vs. 1.8 for Ozempic. Retatrutide also led to more weight loss and better cardiovascular metrics but had higher side effects. Lilly plans to present detailed data later. Analysts see potential for premium pricing and $15B in 2032 sales if approved.

medcitynews.com2 min
OCT 28
$LLYMed

Eli Lilly Stocks Rise After Retatrutide's Head-to-Head Trial Results

Eli Lilly's shares rose 1.21% to $1,297.37 after its experimental drug retatrutide showed superior weight loss and blood sugar control in a head-to-head trial with Ozempic. The 80-week trial in type 2 diabetes patients showed retatrutide patients lost 47.4 pounds on average, compared to 20.9 pounds with Ozempic. However, more retatrutide patients discontinued treatment due to adverse events. Lilly's market value is $1.22 trillion with a P/E ratio of 44.08, indicating high investor expectations.

finance.yahoo.com2 min
OCT 28
$LLYMed

Lilly’s ‘triple-G’ drug tops Novo’s Ozempic in diabetes trial

Eli Lilly's retatrutide outperformed Novo Nordisk's Ozempic in a Phase 3 trial, showing greater blood sugar reduction and weight loss. The highest dose of retatrutide reduced blood sugar by 2.2 percentage points, compared to Ozempic's 1.8 points. Retatrutide also demonstrated significant weight loss, with the highest dose resulting in a 21% reduction, but had higher discontinuation rates due to side effects.

finance.yahoo.com2 min
OCT 28
$LLYHigh

Retatrutide Tops Semaglutide on A1C, Weight in Head-to-Head Trial

Eli Lilly's retatrutide showed greater reductions in HbA1c and weight loss compared to Novo Nordisk's semaglutide in a phase 3 trial. Retatrutide lowered HbA1c by 2.2 points and achieved 19.5-20.9% weight loss, while semaglutide achieved 1.8 points and 9.4% weight loss. Adverse events led to higher discontinuation rates with retatrutide.

ajmc.com3 min
OCT 28
$NVOMedAI 8/10

Novo Nordisk, Eli Lilly, Pfizer, Roche, Amgen, and Viking Therapeutics are developing new weight-loss drugs

Novo Nordisk, Eli Lilly, Pfizer, Roche, Amgen, and Viking Therapeutics are developing new weight-loss drugs. Novo Nordisk is working on CagriSema and amycretin, while Eli Lilly has Foundayo, retatrutide, and EloraTZP. Roche's enicepatide showed 15.5% weight loss in mid-stage trials, with late-stage tests planned for 2027. Amgen's MariTide is in late-stage trials for obesity and related conditions.

qz.com2 min